GIVLAARI® (givosiran) is now listed on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with acute hepatic porphyria (AHP)1
1 April 2026. Medison Pharma Australia Pty Ltd (“Medison”), alongside their partner Alnylam Pharmaceuticals, Inc. (“Alnylam”), is pleased to announce that from April 1st, 2026, GIVLAARI® (givosiran) is listed on the Pharmaceutical Benefits Scheme (PBS) for acute hepatic porphyria in adults and adolescents aged 12 years and older. 1,2,3 Acute hepatic porphyria (AHP) is a […]
Medison Strengthens its Global Commercialization Platform, Appoints Francis Wan as VP, GM Asia Pacific
With a strong track record across APAC, Francis Wan’s appointment marks a powerful acceleration of Medison’s growth in the region ZUG, Switzerland— [October 23rd, 2025] /PRNewswire/ — Medison, the creator of a first-of-its-kind unified global commercialization platform for breakthrough therapies, today announced the appointment of Francis Wan as VP, GM Asia Pacific (APAC) and member […]
OXLUMO® (lumasiran) is now listed on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with primary hyperoxaluria type 1(PH1) [1]
1 October 2025. Medison Pharma Australia Pty Ltd (“Medison”), alongside their partner Alnylam Pharmaceuticals, Inc. (“Alnylam”), is pleased to announce that from October 1st 2025, OXLUMO® (lumasiran) is listed on the Pharmaceutical Benefits Scheme (PBS) for primary hyperoxaluria type 1 (PH1). 1,2,3 Primary hyperoxaluria type 1 (PH1) is a rare disease that is inherited within […]
Health Canada Approves BylvayTM (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
BylvayTM is the first and only medication approved in Canada for the treatment of both Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis TORONTO, ON, September 9, 2025 –Medison and Ipsen announced today that Health Canada has approved BylvayTM (odevixibat) for the treatment of cholestatic pruritus in patients 12 months and older with Alagille Syndrome (ALGS). […]
Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
Strategic appointments reflect Medison’s continued investment in global scale and operational excellence PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ — Medison, the creator of a first-of-its-kind unified global commercialization platform that accelerates the launch of breakthrough therapies in markets beyond the U.S., Western Europe, and Japan, today announced two key additions to its global leadership team: Shay Tamari as Chief Business Officer (CBO) […]